JNJ · 8-K · 20260804PR000167

Leadership Transition

JOHNSON & JOHNSON · 2026-08-04 · Importance 31 · Surprise 42 · In source text

Jennifer Taubert will retire as Executive Vice President and Worldwide Chairman of Johnson & Johnson’s Innovative Medicine business after more than 21 years with the company. The business grew to more than $60 billion in annual revenue under her leadership. Tom Cavanaugh, previously Company Group Chairman for North America, Innovative Medicine, will succeed her and join the Executive Committee effective September 1, 2026, with management emphasizing continuity, pipeline advancement and delivery of medicines worldwide.

Key facts

• Under Jennifer Taubert's leadership, the Company’s Innovative Medicine business grew to more than $60 billion in annual revenue. source
• Tom Cavanaugh will join the Johnson & Johnson Executive Committee, effective September 1, 2026. source
• Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine. source
• Tom Cavanaugh is appointed Executive Vice President, Worldwide Chairman, Innovative Medicine. source
• Tom Cavanaugh most recently led the Company's largest commercial region. source
• Joaquin Duato stated Tom Cavanaugh appointment is effective in advancing the pipeline and bringing transformative medicines to patients around the world. source
• Press release date: August 4, 2026. source
• Jennifer Taubert had over 21-year tenure at Johnson & Johnson. source

Impact estimates